Probably, even in our days, the attainment of CCyR or 1 % BCR-ABL can still be considered the most significant response to target, as this goal has been demonstrated to be associated to the highest probability of long-term survival for CML patients [17–19]. This evidence concerns the gene ABL1 and chronic myelogenous leukemia, BCR-ABL1 positive.